...
首页> 外文期刊>The oncologist >Diagnostic Accuracy of Clinical Biomarkers for Preoperative Prediction of Lymph Node Metastasis in Endometrial Carcinoma: A Systematic Review and Meta‐Analysis
【24h】

Diagnostic Accuracy of Clinical Biomarkers for Preoperative Prediction of Lymph Node Metastasis in Endometrial Carcinoma: A Systematic Review and Meta‐Analysis

机译:子宫内膜癌淋巴结转移术前预测临床生物标志物的诊断准确性:系统评价和荟萃分析

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Background In endometrial carcinoma (EC), preoperative classification is based on histopathological criteria, with only moderate diagnostic performance for the risk of lymph node metastasis (LNM). So far, existing molecular classification systems have not been evaluated for prediction of LNM. Optimized use of clinical biomarkers as recommended by international guidelines might be a first step to improve tailored treatment, awaiting future molecular biomarkers. Aim To determine the diagnostic accuracy of preoperative clinical biomarkers for the prediction of LNM in endometrial cancer. Methods A systematic review was performed according to the Meta‐analysis of Observational Studies in Epidemiology (MOOSE) guidelines. Studies identified in MEDLINE and EMBASE were selected by two independent reviewers. Included biomarkers were based on recommended guidelines (cancer antigen 125 [Ca‐125], lymphadenopathy on magnetic resonance imaging, computed tomography, and 18 F‐fluorodeoxyglucose positron emission tomography/computed tomography [ 18 FDG PET‐CT]) or obtained by physical examination (body mass index, cervical cytology, blood cell counts). Pooled sensitivity, specificity, area under the curve (AUC), and likelihood ratios were calculated with bivariate random‐effects meta‐analysis. Likelihood ratios were classified into small (0.5–1.0 or 1–2.0), moderate (0.2–0.5 or 2.0–5.0) or large (0.1–0.2 or ≥ 5.0) impact. Results Eighty‐three studies, comprising 18,205 patients, were included. Elevated Ca‐125 and thrombocytosis were associated with a moderate increase in risk of LNM; lymphadenopathy on imaging with a large increase. Normal Ca‐125, cytology, and no lymphadenopathy on 18 FDG PET‐CT were associated with a moderate decrease. AUCs were above 0.75 for these biomarkers. Other biomarkers had an AUC 0.75 and incurred only small impact. Conclusion Ca‐125, thrombocytosis, and imaging had a large and moderate impact on risk of LNM and could improve preoperative risk stratification. Implications for Practice Routine lymphadenectomy in clinical early‐stage endometrial carcinoma does not improve outcome and is associated with 15%–20% surgery‐related morbidity, underlining the need for improved preoperative risk stratification. New molecular classification systems are emerging but have not yet been evaluated for the prediction of lymph node metastasis. This article provides a robust overview of diagnostic performance of all clinical biomarkers recommended by international guidelines. Based on these, at least measurement of cancer antigen 125 serum level, assessment of thrombocytosis, and imaging focused on lymphadenopathy should complement current preoperative risk stratification in order to better stratify these patients by risk.
机译:摘要背景下的子宫内膜癌(EC),术前分类是基于组织病理学标准,仅对淋巴结转移的风险(LNM)的风险仅适中的诊断性能。到目前为止,尚未评估现有的分子分类系统以预测LNM。根据国际准则推荐的临床生物标志物优化使用可能是提高量身定制的治疗的第一步,等待未来的分子生物标志物。目的是确定术前临床生物标志物在子宫内膜癌中预测LNM的诊断准确性。方法根据流行病学(驼鹿)指南的观察研究的荟萃分析进行系统审查。由两个独立审查员选择在Medline和Embase中确定的研究。包括的生物标志物基于推荐的准则(癌抗原125 [CA-125],磁共振成像,计算断层扫描和18氟氟氧基葡萄糖正电子断层扫描/计算断层扫描[18 FDG PET-CT])或通过体检获得(体重指数,宫颈细胞学,血细胞计数)。通过双变量随机效应元分析计算汇集敏感性,特异性,曲线下(AUC)的面积和似然比。可能性比例分为小(0.5-1.0或1-2.0),中等(0.2-0.5或2.0-5.0)或大(0.1-0.2或≥5.0)撞击。结果包括18,205名患者的八十三项研究。升高的Ca-125和血栓形成与LNM风险的中等增加有关;淋巴结病在大幅增加的成像。正常的Ca-125,细胞学,18个FDG PET-CT上没有淋巴结病与中等减少相关。对于这些生物标志物,AUC均高于0.75。其他生物标志物具有AUC& 0.75,并且仅产生小的影响。结论CA-125,血小板抑制和成像对LNM风险的巨大和中等的影响,可以改善术前风险分层。对实践常规淋巴结切除术在临床早期子宫内膜癌中的影响并未改善结果,并且与15%-20%的手术相关的发病率相关,强调了改善术前风险分层的需求。新的分子分类系统正在出现,但尚未评估淋巴结转移的预测。本文提供了国际指南推荐的所有临床生物标志物的诊断性能概述。基于这些,至少测量癌抗原125血清水平,血清菌的评估,并关注淋巴结病的成像应补充电流术前风险分层,以便更好地通过风险分层这些患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号